Pioglitazone use and the risk of bladder cancer

This study aimed to identify the risk association between pioglitazone exposure and bladder cancer. A nested case–control study was performed using a representative database randomly sampled from National Health Insurance enrollees. The source cohort consisted of newly diagnosed diabetic patients from 1997 to 2009. Cases were identified as those with a diagnosis of bladder cancer from 2002 to 2009. For each case, four matched control individuals were randomly selected. A multiple logistic regression model was used to estimate the relative magnitude of risk in relation to the use of pioglitazone. In total, 259 cases and 1036 controls were identified. The prevalent use of pioglitazone is similar in cases and controls (adjusted odds ratio, 1.20; 95% confidence interval, 0.58–2.49). Compared to nonusers, these values were 1.08 (0.41–2.88) for those with cumulative pioglitazone use ≤ 8268 mg and 1.35 (0.48–3.79) for those with cumulative pioglitazone use > 8268 mg. This study does not provide support for the risk association between pioglitazone exposure and bladder cancer. Further confirmation is needed due to the limitation of small case number with relatively shorter exposure duration and lower cumulative dose.

[1]  Samuel M. Cohen,et al.  Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  K. Hattori,et al.  Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. , 2001, The American journal of pathology.

[3]  S. Cohen.  Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  C. Tseng.  Pioglitazone and Bladder Cancer , 2012, Diabetes Care.

[5]  V. Steele,et al.  Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine‐induced urinary bladder cancers , 2008, International journal of cancer.

[6]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[7]  Y. Kawahito,et al.  Expression of peroxisome proliferator‐activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists , 2003, International journal of cancer.

[8]  S. Cohen.  Effects of PPARγ and Combined Agonists on the Urinary Tract of Rats and Other Species , 2005 .

[9]  Kenji Ishimoto,et al.  The Role of PPARs in Cancer , 2008, PPAR research.

[10]  W. Bilker,et al.  Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone , 2011, Diabetes Care.

[11]  J. Dormandy,et al.  Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes , 2009, Drug safety.

[12]  Elisabetta Poluzzi,et al.  Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting , 2011, Diabetes Care.